TWO-YEAR FATE STUDY OF PACATAL-TREATED PATIENTS
PAUL E. FELDMAN M. D.1
1 Director of Research and Education, Topeka State Hospital, Topeka, Kan.
It may be implied from the data collected that tolerance formation does not occur and that the maintenance dosage is substantially smaller than the original therapeutic dosage. There is no evidence of continued toxicity and those patients treated continuously with Pacatal for 3 years are remarkably free of side effects. Remission following Pacatal therapy appears to be a stable one and only 8
% of the released patients have found it necessary to return to the hospital.
The findings in this study are similar to those obtained in a 2-year follow-up study of Thorazine-treated patients.
